Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLongo-Muñoz, Federico
dc.contributor.authorCastellano, D.
dc.contributor.authorAlexandre, Jerome
dc.contributor.authorChawla, Sant P.
dc.contributor.authorFernández, Cristian
dc.contributor.authorKahatt, Carmen
dc.contributor.authorSanz Garcia, Enrique
dc.date.accessioned2022-09-15T08:13:53Z
dc.date.available2022-09-15T08:13:53Z
dc.date.issued2022-09
dc.identifier.citationLongo-Muñoz F, Castellano D, Alexandre J, Chawla SP, Fernández C, Kahatt C, et al. Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. Eur J Cancer. 2022 Sep;172:340–8.
dc.identifier.issn0959-8049
dc.identifier.urihttp://hdl.handle.net/11351/8198
dc.descriptionLurbinectedin; Neuroendocrine tumours; Small cell
dc.description.abstractBackground Patients with neuroendocrine tumours (NETs) need alternative therapies after failure of first-line therapy. Patients and methods This phase II trial evaluated lurbinectedin, a selective inhibitor of oncogenic transcription, at 3.2 mg/m2 as a 1-h intravenous infusion every 3 weeks in 32 NETs patients treated in the second- or third-line setting. The primary efficacy endpoint was overall response rate (ORR) according to RECIST v1.1 assessed by the investigators. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety. Results Two of 31 evaluable patients had confirmed partial responses (ORR = 6.5%; 95%CI, 0.8–21.4%). Median DoR was 4.7 months (95% CI, 4.0–5.4 months), median PFS was 1.4 months (95% CI, 1.2–3.0 months) and median OS was 7.4 months (95% CI, 3.4–16.2 months). Lurbinectedin showed an acceptable, predictable and manageable safety profile. The most common grade 3/4 toxicity was neutropenia (40.6%; grade 4, 12.4%; febrile neutropenia, 3.1%). Conclusions Considering the exploratory aim of this trial that evaluated a heterogeneous population of NETs patients, and the signs of antitumour activity observed (two confirmed partial responses and seven long disease stabilisations), further development of lurbinectedin is warranted in a more selected NETs population.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesEuropean Journal of Cancer;172
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectTumors neuroendocrins - Tractament
dc.subjectTeràpia intravenosa
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshNeuroendocrine Tumors
dc.subject.mesh/drug therapy
dc.subject.meshInfusions, Intravenous
dc.subject.meshTreatment Outcome
dc.titleLurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.ejca.2022.06.024
dc.subject.decstumores neuroendocrinos
dc.subject.decs/farmacoterapia
dc.subject.decsinfusiones intravenosas
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1016/j.ejca.2022.06.024
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Longo-Muñoz F] Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain. [Castellano D] Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain. [Alexandre J] Medical Oncology, Cochin Hospital, AP-HP, Paris, France. [Chawla SP] Medical Oncology, Sarcoma Oncology Center, Santa Monica CA 90403, USA. [Fernández C, Kahatt C] Clinical R&D, PharmaMar, Colmenar Viejo, Spain. [Sanz-García E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid35830841
dc.identifier.wos000829363200011
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record